Professional Documents
Culture Documents
Objectives
1. Discuss the importance of oral and dental care
for patients with human immunodeficiency virus
(HIV) infection.
2. Review the classification of orofacial lesions
associated with HIV infection in adults and
children.
3. Describe the clinical presentation and
management of the most common oral
manifestations of HIV infection.
Key Points
1. Oral health care is an important part of HIV
primary care.
2. Oral manifestations are common clinical findings
in children and adults with HIV infection.
3. Early diagnosis and management of oral mani
festations is important to prevent complications
and improve quality of life.
Non-Hodgkins lymphoma
Periodontal disease
Linear gingival erythema
Necrotizing (ulcerative) gingivitis
Necrotizing (ulcerative) periodontitis
Bacterial infections
Mycobacterium avium-intracellulare
Mycobacterium tuberculosis
Melanotic hyperpigmentation
Necrotizing (ulcerative) stomatitis
Salivary gland disease
Dry mouth due to decreased salivary flow rate
Unilateral or bilateral swelling of the major
salivary glands
Thrombocytopenic purpura
Ulceration NOS (not otherwise specified)
Lesions seen in HIV infection
Viral infections
Herpes simplex virus
Human papillomavirus (wart-like lesions)
Condyloma acuminatum
Focal epithelial hyperplasia
Verruca vulgaris
Varicella zoster virus
Herpes zoster
Varicella
1
2
Bacterial infections
Actinomyces Israel
Escherichia coli
Klebsiella pneumoniae
Cat-scratch disease
Drug reactions (ulcerative, erythema multiforme,
lichenoid, toxic epidermolysis
Epithelioid (bacillary) angiomatosis
Neurologic disturbances
Facial palsy
Trigeminal neuralgia
185
Oral candidiasis
Pseudomembranous
Erythematous
Angular cheilitis
Herpes simplex virus infection
Linear gingival erythema
Viral infections
Cytomegalovirus
Human papillomavirus
Molluscum contagiosum
Varicella zoster virus
Herpes zoster
Varicella
Neoplasms
Kaposis sarcoma and non-Hodgkins lymphoma
Oral hairy leukoplakia
Tuberculosis-related ulcers
186
Comments
Oral
Topical
Topical
Candidiasis
Nystatin (Mycostatin) Nystatin suspension 200,000-
(Erythematous,
Oral gel: apply gel q8h 400,000 U/day divided in 4-6 doses,
Pseudomembranous, or q6h, for 10-14 days for 14 days
and Hyperplastic) Cream: Apply q12h, for Clotrimazole troches 10 mg q8h or
10-14 days q6h, for 4 weeks
Gentian violet 1% aqueous solution
Systemic painted in the affected areas q8h
Nystatin (Mycostatin) antifungal agents are administered
400,000-600,000 U q6h,
for 14 days
Systemic
Ketoconazole (Nizoral) Ketoconazole 3.5-6.6 mg/kg/day in
200-400 mg PO q.d. a single dose
Fluconazole (Diflucan) Fluconazole 6 mg/kg on day 1, then
50-100 mg PO q.d. 3 mg/kg qd, up to 2 weeks
Itraconazole (Sporanox) Itraconazole 100 mg PO, daily for
(Capsules or solution) children older than 3 years
200 mg PO qd for 7 days
Amphotericin B10 mg Prophylaxis
IVq6h, for 10 days
Clotrimazole 10 mg PO q8h or
q12h for long period
Prophylaxis
Nystatin 100,000-400,000 U PO
Fluconazole 100 mg q12h for long period
PO qwk, for long period Fluconazole 3-6 mg/kg PO daily or
weekly for long period
Angular
Topical
Topical
Cheilitis
Nystatin-triamcinolone Nystatin-triamcinolone (Mycolog II)
(Mycolog II) ointment ointment applied on the affected
applied on the affected areas after meals and at bedtime
areas after meals and
Clotrimazole 1% (Mycelex) cream
at bedtime
Miconazole 2% cream applied q12h
Clotrimazole 1% on the affected areas, for 1-2 weeks
(Mycelex) cream
Miconazole 2% cream
applied q12h on the
affected areas, for 1-2
weeks
Herpes Simplex
Systemic
Systemic
Virus (HSV)
Acyclovir (Zovirax)
Acyclovir 10 mg/kg PO q4h or q6h
Infection 800 mg PO q4h,
Acyclovir 10 mg/kg IV q8h
for 10 days
Foscarnet 24-40 mg/kg PO q8h, for
Foscarnet 24-40 mg/kg resistant herpetic lesions
PO q8h, for resistant
herpetic lesions
Linear Gingival
Local
Local
Erythema
Scaling and root planing Scaling and root planing
(LGE)
0.12% Chlorhexidine
0.12% Chlorhexidine gluconate
gluconate (Periogard, (Periogard, Peridex) 0.5 oz q12h
Peridex) 0.5 oz q12h rinse, for 30 sec. and spit
rinse, for 30 sec. and spit
188
Systemic
Surgical removal of the parotid
Non-steroidal anti-inflammatories gland may be necessary for
Analgesics esthetic reasons.
Antibiotics
Steroids
Oral Hairy
Local
Local
Recurrence often occurs after the
Leukoplakia (OHL) Podophyllin resin
Podophyllin resin 25% 1-2 applica- treatment is discontinued.
25% 1-2 applications tions on the affected areas, at
OHL is rare in children.
on the affected areas, at 1 week apart Symptomatic and extensive lesions
1 week apart
Retinoic acid (Tretinoin) may require topical treatment.
Retinoic acid (Tretinoin) Surgical excision
OHL has been shown to disappear
Surgical excision in patients receiving zidovudine
(AZT).
Systemic
Acyclovir (Zovirax)
800 mg PO q4h or q6h,
for 14 days
Famciclovir 500 mg PO
q8h, for 5-10 days
Valacyclovir 1000 mg
PO q8h, for 5-10 days
Necrotizing
Local
Local
Prolonged use of chlorhexidine
Ulcerative
Debridement of
Debridement of affected areas may cause staining of teeth,
Gingivitis (NUG), affected areas
Irrigation with povidon-iodine tongue, and restorations; taste
Irrigation with povidon- (10% Betadine) alteration; and mucosal
Necrotizing iodine (10% Betadine) 0.12% chlorhexidine gluconate desquamation and irritation.
Ulcerative
0.12% chlorhexidine (Peridex, Periogard) mouth rinse
Metronidazole should not be
Periodontitis (NUP), gluconate (Peridex, q12h given to patients taking
Periogard) mouth rinse didanosine (ddI) or zalcitabine
Necrotizing q12h (ddC), because it may potentiate
Stomatitis (NS) peripheral neuropathy.
Comments
Necrotizing
Systemic
Systemic
(See chart on previous page)
Ulcerative
Metronidazole (Flagyl) Metronidazole (Flagyl) 15-35 mg/kg
Gingivitis (NUG), 250 mg PO q8h or PO q8h, for 7-10 days
500 mg q12h, for 7-10 days Clindamycin (Cleocin) 20-30 mg/kg
Necrotizing
Clindamycin (Cleocin) PO q6h, for 7 days
Ulcerative
150 mg PO q6h or
Amoxicillin clavulanate (Augmentin)
Periodontitis (NUP), 300 mg PO q8h, for 7 days 40 mg/kg PO q8h, for 7 days
Amoxicillin clavulanate
Necrotizing (Augmentin) 250 mg PO
Stomatitis (NS) q12h, for 7 days
Oral Ulcers
Topical
Topical
Major aphthous ulcers usually
(Recurrent
Triamcinolone in
Triamcinolone in Carboxymethyl- require systemic steroids.
Aphthous Ulcers) Carboxymethylcellulose cellulose 0.1% paste applied in a
Aphthous ulcers may be exacebated
0.1% paste thin layer q6h daily by stress.
Betamethasone
Betamethasone phosphate:
Iron, vitamin B12, and folate
phosphate: 0.5 mg tablet dissolved in 10 ml deficiencies should be ruled out.
0.5 mg tablet dissolved mouthwash and rinse q4h
Dexamethasone elixir should be
in 10 ml mouthwash spray on ulcer (1 spray = 100 g) used for multiple ulcers or ulcers
and rinse q4h up to 800 g not accessible for topical applica-
spray on ulcer (1 spray Fluocinonide (Lidex) 0.05% tion.
= 100 g) up to 800 g ointment q4h
Thalidomide is indicated only
Fluocinonide (Lidex)
Dexamethasone elixir (0.5 mg/5ml) when recurrences are severe
0.05% ointment applied rinse and expectorate and frequent.
on ulcer q4h
The treatment with Thalidomide
Dexamethasone elixir
Systemic should be monitored thoroughly
(0.5 mg/5ml) rinse and Prednisone 2 mg/kg q6h, for 5-7 due to its teratogenicity. Birth
expectorate days with gradual tapering control measures are required.
Systemic
Prednisone starting at
30-40 mg PO daily with
taper over 1 month for
severe disease resistant
to topical agents
Thalidomide 200 mg PO
daily
Oral Warts
Topical
Topical
The recurrence rate is high.
Podophyllin resin 25% Podophyllin resin 25% applications Concurrent therapeutic approaches
applications q6h for q6h for long period should be considered.
long period
Surgical excision
Surgical excision
Laser ablation
Laser ablation
Cryotherapy
Cryotherapy
Systemic
Cimetidine (Tagamet)
600 mg PO q6h, for long
period (months)
Interferon alfan3 SC/IM
3,000,000 U (1 ml) qwk,
for several weeks
Abbreviations used in Table 3: PO = per os (by mouth); IV = intravenous; qd = every day; qwk = every week; q2h = every two hours;
q4h = every four hours; q6h = every six hours; q8h = every 8 hours; q12h = every 12 hours.
190
General Management
Considerations
To prevent the need for expensive dental services, it
is imperative to treat the oral manifestations of HIV
infection at all levels of care. Personal oral hygiene
practices, such as tooth brushing and use of interdental
cleaning aids, are the most effective ways of maintaining
good oral health.
At the primary level of oral care, prevention of oral
diseases takes priority. Prevention involves improving
oral hygiene awareness through health education at the
individual and community levels. Oral health education
messages should be made visible in all community
forums. Home-based care providers should undergo
training in basic oral hygiene practices so that they
can impart these to patients under their care. Use of
simple materials such as warm salty mouth rinse or
commercial mouthwash (chlorhexidine) can improve
basic oral hygiene cost-effectively. Patients whose manual
dexterity is intact should be taught appropriate brushing
techniques. Other adjuvant oral hygiene methods, such as
flossing and use of interdental toothbrushes, will depend
on the availability and affordability of supplies.
The secondary level of oral care involves visits to clinical
care facilities. Depending on local resources, the health
cadre available at this level may range from nursing
staff at a health center to primary care physicians. In
some countries, health centers may have no oral health
personnel or may offer only relief of pain with analgesics
and extractions. Health care workers at this level should
be trained to recognize suspicious lesions that may be
oral manifestations of HIV infection, and they should
know when and where to refer patients to a higher level
of oral care.
At the tertiary level of oral care, a dentist should be
available to make definitive diagnoses of oral lesions and
provide professional oral services such as prophylaxis,
restorations, biopsies, and the prescription of appropriate
medication.
Acknowledgment
We thank Professor Sudeshi Naidoo, Department of
Community Dentistry, Faculty of Dentistry and WHO
Collaborating Centre, University of the Western Cape,
South Africa, for providing the pictures of oral lesions
used in this chapter.
References
1. Arendorf TM, Bredekamp B, Cloete CAC, et al. Oral
manifestations of HIV infection in 600 South African
patients. J. Oral Pathol. Med. 1998;27:176-179.
2. Winfert M, Grimes RM, Lynch DP. Oral
manifestations of HIV infection. Ann. Intern. Med.
1996;125:485-496.
3. Kamiru HN, Naidoo S. Oral HIV lesions and oral
health behaviour of HIV positive patients attending
Queen Elizabeth II Hospital, Maseru, Lesotho. SADJ
2002;57:479-482.
4. Patton LL, Phelan JA, Ramos-Gomez FJ, et al.
Prevalence and classification of HIV-associated oral
lesions. Oral Dis. 2002;8(Suppl 2):98-109.
5. Chapple ILC, Rout PJ, Basu MK. Gingival Kaposis
sarcoma: the first indication of HIV infection. Dent.
Update 1992;19:296-301.
6. Klein RS, Harris CA, Small CB, et al. Oral candidiasis
in high-risk patients as the initial manifestations of
the acquired immunodeficiency syndrome. N. Engl. J.
Med. 1984;311:354-358.
7. Centers for Disease Control and Prevention. 1993
revised classification system for HIV infection and
expanded surveillance case definition for AIDS
among adolescents and adults. MMWR Recomm. Rep.
1993;41(RR-17):1-19.
8. Ramos-Gomez FJ, Petru A, Hilton JF. Oral
manifestations and dental status in paediatric HIV
infection. Int. J. Paediatr. Dent. 2000;10:3-11.
9. Magalhaes GM, Bueno DF, Serra E. Oral
manifestations of HIV positive children. J. Clin.
Pediatr. Dent. 2001;25:103-106.
10. Nicolatou O, Theodoridou M, Mostrou G. Oral
lesions in children with perinatally acquired
immunodeficiency virus infection. J. Oral Pathol.
Med. 1999;28:49-53.
11. Begg MD, Lamster IB, Panageas KS. A prospective
study of oral lesions and their predictive value for
progression of HIV disease. Oral Dis. 1997;3:176183.
12. Chapple ILC, Hamburger J. The significance of oral
health in HIV disease. Sex Transm. Inf. 2000;76:236243.
13. Katz MH, Mastrucci T, Leggott PJ, et al. Prognostic
significance of oral lesions in children with
perinatally acquired human immunodeficiency virus
infection. Am. J. Dis. Child. 1993;147:45-48.
192
193